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INTRODUCTION
 Stroke is the third leading cause of death 
worldwide and is one of the most important factors 
of disability in different countries.1-3 Although 
stroke appears to be a disease of the elderly, but 
one third of patients have less than 65 years of 
age.4 Among them, 50 to 70 percent of patients 
get back their primary function, 15 to 30 percent 
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ABSTRACT
Objectives: Intravenous thrombolytic therapy has established acceptable results in treating ischemic 
stroke. However, there is little information on treatment outcome especially in different subtypes. The 
aim of current study was to evaluate early and intermediate prognosis in intravenous thrombolytic therapy 
for acute ischemic stroke subtypes.
Methodology: Forty eligible patients (57.5% male with mean age of 63.18±13.49 years) with definite 
ischemic stroke who were admitted to emergency department of Imam Reza University Hospital, in the 
first 180 minutes after occurrence received recombinant tissue plasminogen activator. All investigation 
findings were recorded and stroke subtypes were determined according to the Causative Classification 
of Stroke System. Stroke severity forms including modified Rankin Scale (mRS) and National Institutes of 
Health Stroke Scale (NIHSS) scores were recorded for all patients in first, seven and 90 days after stroke 
and disease outcome was evaluated.
Results: The etiology of stroke was large artery atherosclerosis in 20%, cardio-aortic embolism in 45%, 
small artery occlusion in 17.5% and undetermined causes in 17.5%. NIHSS and mRS scores were significantly 
improved during time (P < 0.001 in both cases). Three months mortality rate was 25%. Among the etiologies, 
patients with small artery occlusion and then cardio-aortic embolism had lower NIHSS score at arrival (P 
= 0.04). Caplan-meier analysis showed that age, sex and symptom to needle time could predict disease 
outcome.
Conclusion: Intravenous thrombolytic therapy is accompanied by good early and intermediate outcome 
in most patients with ischemic stroke. Small artery occlusion subtype had less disease severity and higher 
improvement.
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remain incapable for ever and 20 percent are in 
need of hospital care for three months.5 With better 
understanding of the pathophysiology of nerve 
damage and introduction of new drugs, treatment 
regimen includes anticoagulation and thrombolysis 
drugs besides invasive interventions.6
 Recombinant tissue plasminogen activator 
(rtPA) in the treatment of cerebral ischemic stroke 
has been confirmed by American Food and Drug 
Administration (FDA) in 1996.7 In America, this 
drug causes symptoms improvement of stroke 
in more than 50% of cases with minimal serious 
complications.8 However, only 3 to 8.5% of patients 
were eligible for rtPA.9 Several studies about cost - 
effectiveness of this drug compared with the high 
cost and potential side effects of this drug have 
been performed. Results show that use of rtPA 
has increased for ischemic stroke treatment due to 
reduction in patient morbidity and hospitalization 
time and no need to give long-term treatment, also 
saving millions of dollars.10
 Studies that evaluate the prognosis of etiologic 
subtypes in patients receiving intravenous 
thrombolytic therapy are limited and these studies 
mainly have reported complications following 
drug consumption.11-13 The aim of this study was to 
evaluate the prognosis of intravenous thrombolytic 
therapy in ischemic stroke subtypes to investigate 
the early (7 days) and intermediate (3 months) 
effect of desired drug.
METHODOLOGY
 This study was performed by a stroke team 
and rtPA was administrated in the treatment of 
acute ischemic stroke as a prospective descriptive-
analytical study. The study population consisted 
of 40 patients who were hospitalized at Imam 
Reza Hospital Emergency during September 2011 
to March 2012 with symptoms of suspected stroke 
and in 180 minutes of the onset of their clinical 
symptoms. This study was database of a large 
trial that is being conducted and named as Tabriz 
Thrombolytic Therapy for Acute Ischemic Stroke 
(T3-AIS).
 Inclusion criteria was patients under the Cincinnati 
Pre-hospital Stroke Scale with at least one of three 
symbols including unilateral facial weakness, 
unilateral upper extremity weakness (Arm drift) 
and abnormal speech, and less than 180 minutes 
from the onset of their  symptoms. Of all patients in 
the triage room laboratory sampling and brain CT 
scan were performed. With detailed history taking 
and physical examination contraindication of rtPA 
administration from the form shared guideline 
of American Heart Association and American 
Stroke Association (year 2010)14 (that indications 
and contraindications of rtPA administration 
has determined) was evaluated and forms were 
completed. With definite diagnosis of ischemic 
stroke and in the absence of rtPA administration 
contraindications, patients were admitted to the 
neurology ICU, written consent was obtained from 
patient’s relatives.
 Clinical Assessment Forms of stroke using 
National Institutes of Health Stroke Scale (NIHSS) 
and modified Rankin Scale (mRS) were completed 
for all patients and in the next step was attempted 
to administer rtPA. Patients after this emergency 
phase were undergoing routine investigations 
according to case and to determine the etiology of 
the disease.
 All findings of medical history, physical 
examination, brain imaging, vascular imaging, 
cardiac investigations and other items were 
recorded. In accordance with the Causative 
Classification of Stroke (CCS)15 specific subtype of 
Fig.1: Interval of symptoms presentation until 
TPA administration in various etiologies. Fig.2: mRS scale changes over the 3 months.
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stroke was determined. The CCS is a questionnaire-
style classification scheme for ischemic stroke. The 
automated algorithm reports the stroke subtype 
and a description of the classification rationale. It 
arranges the patient into 5 subgroups (large artery 
atherosclerosis, cardio-aortic embolism, small 
artery occlusion, other causes, and undetermined 
causes) and each subtype of stroke subdivided to 
evident, probable and possible. The undetermined 
group is divided into cryptogenic embolism, 
other cryptogenic, incomplete evaluation, and 
unclassified categories and NIHSS and mRS were 
determined for each patient on day 1, 7 and 90.
 This study was designed as ongoing 
administration of thrombolytic therapy and in this 
regard, legal and ethical standards were considered.
Statistical Analysis: Obtained data are expressed as 
mean ± standard deviation, frequency, percentage 
and SEM (if necessary). Data were analyzed by 
SPSS™ 17 software. Quantitative variables were 
compared by using Student T-test and one way 
ANOVA and multiple regressions and qualitative 
variables have been compared by using Chi-
Square Test and Fisher’s Exact Test. Quintile and 
Cox regression analysis was used to determine 
the disease prognosis predicting factors. In all 
investigated cases, the results have been known 
statistically significant in case of P ≤ 0.05.
RESULTS
 In this study 40 patients with ischemic stroke 
underwent rtPA treatment with mean age of 
63.18±13.49 (38 – 88 years) with a median of 67.50 
year. The patients were 23 (57.5%) male and 17 
(42.5%) female. Average systolic blood pressure 
was 149.18±31.05 mmHg and mean diastolic blood 
pressure was 88.08±14.16 mmHg.
 As regards past medical or social history, 24 
patients (60%) had HTN, 10 (25%) had Diabetes 
Mellitus, 9 (22.5%) were smokers, 5 (12.5%) had 
hyperlipidemia. AF was detected in 9 (22.5%), and 
11 (27.5%) suffered from IHD. Embolus history was 
noted in 9 (22.5%) out of which 7 cases (17.5%) were 
ischemic strokes or TIA and in 2 cases (5%) was 
associated with systemic emboli. Mean NIHSS score 
on admission equaled 13.38±4.46 with a median of 
13. The highest and the lowest scores were 3 and 
27 respectively. NIHSS score in 17 patients (42.5%) 
was more than 15 or in other words had severe 
stroke on admission.
 On admission mRS score average was 4±1.25 
with a median of 4. The highest and the lowest 
scores were 1 and 5 respectively. Using the CCS 
to determine etiologic subtype of stroke 8 (20%) 
large vessel atherosclerosis, 18 (45%) cardio-
aortic embolus, 7 (17.5%) small vessel occlusion 
and 7 (17.5%) no known cause were involved. 
With the CSS subdivision, patients were placed 
in 9 subgroups as follows:7 (17.5%) documented 
large vessel atherosclerosis, 2 (5%) probable large 
vessel atherosclerosis, 9 (22.5%) documented 
cardio-aortic emboli, 2 (5%) probable cardio-aortic 
emboli, 7 (17.5%) possible cardio-aortic, 7 (17.5%) 
documented small vessel occlusion, 2 (5%) with 
obviously unknown factor, 3 (7.5%) with probable 
unknown cause, and 1 (2.5%) with possible cause.
Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Subtypes
Fig.3: NIHSS scale changes over the 3 months.
Fig.4: Kaplan-Meier curve of total patients survival.
Fig.5: Kaplan-Meier curve of patients based on gender.
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 However in one instance, CSS software grouped 
one of the patients to probable large vessel athero-
sclerosis, probable cardio-aortic emboli, and unclas-
sified unknown etiology and in another instance 
one case was classified both as evident cardio-aortic 
emboli and possibly unknown etiology; we consid-
ered them to be probable and evident respectively. 
Fig.1 demonstrates the period between onset of 
symptoms and rtPA administration in various eti-
ologies. As seen the patients with small vessel oc-
clusion sought medical care more immediately. No 
significant difference between groups were seen in 
this respect (P =0.69).
 Fig. 2 and 3 show the trends for changes in mRS 
and NIHSS criteria during 3 months. As shown 
in the diagrams as time elapsed mRS and NIHSS 
scores decreased to a significant degree meaning 
recovery has occurred (P <0.001 in both cases). At 
the end of 3 months there were 10 deaths (25%) 
of which four (10%) were due to direct stroke and 
rtPA complication, while enough follow up data is 
not available about other six patients. Two death 
occurred in the first week and the other between 
week one and month three. Considering low sam-
ple size in this study, it was not possible to compare 
patients regarding CCS criteria; however patients 
were investigated as to the etiologies.
 Death at the end of three months had occurred in 
one case (12.5%) with large vessel atherosclerosis, 
in 6 (33.3%) of cases with cardio-aortic emboli, in 2 
cases (28.6%) with small vessel occlusion and one 
(14.6%) of those having no specified etiology. It was 
not feasible to compare data statistically because of 
uneven distribution.
 Table-I, shows NIHSS scores for different etiolo-
gies in different stages. Patients with small vessel 
occlusion and then cardio-aortic emboli have lower 
NIHSS scores or in fact less severe stroke (P =0.04). 
However in these two groups conditions worsened 
and in two other groups changed for better till day 
7. At the end of three months the group with small 
vessel occlusion had lower NIHSS score and signifi-
cant recovery; although no statistically significant 
difference exist between two groups.
 Table-II, shows mRS scores for different etiolo-
gies in different stages. Cardio-aortic group had the 
highest mRS scores on admission. Following treat-
ment decrease in MRS and recovery in small vessel 
occlusion on day 7 and after three month was high-
er; however no statistically significant difference 
was observed. Applying Quintile regression test 
was not able to identify predictors for prognosis 
based upon mRS, NIHSS. Hence in this respect Cox 
regression was applied in which the three variables: 
age, sex, and time between onset of symptoms and 
administration of rtPA were capable of yielding a 
meaningful survival prognosis. It should be noted 
that symptom to needle time and confidence inter-
val for Hazard Ratio was wide due to scarcity of 
cases.
 Fig. 4 and 5 demonstrate Kaplan-Meier analy-
sis result for three-month survival in terms of age 
which was 1.19 ± 0.062 (P < 0.001, z = 3.34, CI: 1.07 
– 1.32), gender was 22.30 ± 23.20 (P = 0.003, z = 2.98, 
CI: 2.90 – 171.33) and symptoms was 1.03 ± 0.01 (P = 
0.04, z = 1.99, CI: 1.0004 – 1.06).
DISCUSSION
 Stroke leads to very high medical costs to healthcare 
systems1,2 and to reduce it, administration of rtPA 
in patients with stroke had come into attention. The 
minimum benefit of increasing the use of rtPA in the 
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Table-I: NIHSS score at different stages in the various etiology of diseases based on mean; 
NIHSS: National Institutes of Health Stroke Scale.
 Large artery cardio aortic Occlusion of Undetermined P value
 atherosclerosis embolism small vessels causes
Admission NIHSS 14.62 ± 5.85 6.56 ± 1.54 3.62 ± 1.37 14.14 ±6.38 0.04
Seventh day NIHSS 13.12 ± 8.40 10.50 ± 8.56 6.86 ± 2.13 9.43 ± 3.88 0.2
Third month NIHSS 7.29 ± 5.02 4.92 ± 1.65 1.00 ± 0.54 3.33 ± 1.25 0.15
Note: Data are presented as Mean ± SD.
Table-II: mRS score at different stages in the various etiologies of diseases based on mean; 
mRS: Modified Rankin Scale.
 Large artery cardio aortic Occlusion of Undetermined Quartile P value
 atherosclerosis embolism small vessels causes (25 – 75%)
Admission mRS 3.88 ± 1.8 4.38 ± 0.88 3.14 ± 1.34 4.14 ± 0.9 3.25 0.17
Seventh day mRS 3.12 ± 1.95 3.12 ± 1.74 1.71 ± 0.74 2.71 ± 1.89 3.75 0.4
Third month mRS 1.71 ± 1.6 1.58 ± 0.54 0.2 ± 0.2 1.17 ± 0.6 3 0.38
Note: Data are presented as Mean ± SD.
treatment of patients with ischemic stroke include 
rapid evacuation of hospital beds, reduction of need 
in and equipment reducing the burden of nursing 
care.11 However, lack of infrastructural facilities, 
expensive drugs, side effects of drug prescription 
and low golden time from onset of symptoms until 
the drug administration has limited the using of 
this medication.11-13
 Yip et al has concluded that even with slight 
increase in rtPA administration rate in Canada 
significant savings in Health Care System 
expenditures were obtained.1 In two other studies 
done by Coan et al increasing rtPA administration 
has been reiterated.16,17 However few studies 
have investigated the prognosis of patients after 
intravenous thrombolytic therapy according to the 
etiologolic subtypes.11-13,18-20 Imam Reza Teaching 
Hospital, a tertiary health center is annually visited 
by over 1000 ischemic stroke patients. Physicians 
and nurses are experienced in treatment, having 
capability for neuro imaging, consultation and brain 
surgery in a round the clock mode. In addition it 
has facilities of intensive care units, physiotherapy 
and nutrition  consultations which has provided the 
infrastructure required for routine and systematic 
administration of rtPA by triage of ischemic stroke 
patients and setting up special team. Current study 
has investigated short and long-term prognosis of 
intravenous thrombolytic therapy within 3 hours in 
ischemic stroke subgroups of 40 patients admitted 
with stroke.
 Complications associated with drug especially 
intracerebral hemorrhage (ICH) has deterred 
physicians from using it.12 We too encountered 
17.5% ICH rate, four of which were symptomatic and 
resulted in death. In a study by Walters et al on 120 
patients, 16 episodes of acute cerebral hemorrhage 
occurred, 5 of which were symptomatic.21 Studies 
have cited different figures for cerebral hemorrhage 
prevalence varying from 3-13%.12,13,21 This can be 
attributed to general health of patients studied in 
each group and presence or absence of diseases and 
underlying etiology in each etiology.
 This study has demonstrated significant recov-
ery in mRS and NIHSS scores following treatment. 
3-month mortality was 25% and severe morbidity 
occurred in 10% of patients. About  65% of patients 
had no or least morbidity according to mRS criteria. 
Figueroa- Reyes et al studied outcome of ischemic 
stroke following rtPA in 19 patients out of which 
63% suffered no or least morbidity, 26% medium 
and 5% severe morbidity. One case died one day 
after thrombolysis.22
 In Walters et al survey over 3 month follow up 
period, 31% of patients enjoyed favorable results 
(MRS 0-1), 22% gained average results (MRS 2-3) 
and 21% had poor results (MRS 4-5) with 21% 
mortality.21 Discrepancy in mortality observed in 
various studies can be due to difference in sample 
sizes. Generally it can be noted that in all studies 
most of patients take benefit out of rtPA treatment 
and recover with sufficient restoration of functions. 
Key outcomes such as disability, death and 
recurrence following ischemic stroke differ between 
subgroups.23,24 In our survey etiologies were large 
vessel atherosclerosis in 20%, cardio-aortic emboli 
in 45%, and small vessel occlusion in 17.5%. Of 
all etiologies, small vessel occlusion followed by 
cardio-aortic emboli had lowest NIHSS scores. 
Patients suffering from small vessel occlusion 
visited the hospital earlier than others.
 This study also showed that recovery within three 
months in patients with small vessel occlusion was 
higher than others. After three months death oc-
curred in 12.5% of patients with large vessel athero-
sclerosis, 33.3% of patients with cardio-aortic em-
boli, 28.6% with small vessel occlusion and 14.3% of 
episodes had no known etiology. Other studies have 
shown small vessel involvement and lacunar in-
farct to have better recovery and less recurrence.25,26 
Severity of neurologic deficit in the beginning of the 
disease has been postulated as the most important 
factor in prognosis. Accordingly one study showed 
NIHSS over 17 and age over 70 to be the best one-
year prognostic factors of poor outcome.27 How-
ever in our study despite high NIHSS scores and 
advanced ages in patients with poor prognosis, no 
significant difference was observed in this respect. 
We saw that age, sex and time between symptoms 
onset and drug administration were capable of 
forecasting disease outcome. Similarly Dharmasa-
roja et al have stated that age over 70, severe stroke 
(NIHSS ≥ 15) and Intracranial Hemorrhage (ICH) 
are conversely related to early recovery.28
CONCLUSION
 Intravenous thrombolytic therapy is accompanied 
by favorable short and long-term results in patients 
with ischemic stroke. Symptoms are less severe 
and recovery is higher in patients with small vessel 
occlusion. Age, sex and time between symptoms 
onset and drug administration were capable of 
forecasting disease outcome. Considering findings 
of this study intravenous thrombolytic therapy 
can be recommended especially in milder episodes 
and small vessel occlusion subgroups. However 
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due to recent administration of rtPA in our center 
and small sample size of our study it was not 
feasible to evaluate statistical difference between all 
subgroups. Conducting a study with larger sample 
size can yield better and more precise results.
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